Jiangsu Aidea Pharmaceutical Co Ltd (688488) — Cash Flow-to-Debt Ratio
Jiangsu Aidea Pharmaceutical Co Ltd (688488) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥3.56 Million could theoretically repay 0% of its total liabilities (CN¥762.97 Million) in one year. See 688488 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jiangsu Aidea Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Jiangsu Aidea Pharmaceutical Co Ltd across 9 annual periods. Also explore Jiangsu Aidea Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2024)
Year-by-year debt coverage analysis for Jiangsu Aidea Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see 688488 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.05x | CN¥-37.50 Million | CN¥802.48 Million | ▲ +82.5% |
| 2023 | -0.27x | CN¥-166.22 Million | CN¥621.03 Million | ▼ -31.9% |
| 2022 | -0.20x | CN¥-92.55 Million | CN¥456.23 Million | ▼ -104.7% |
| 2021 | -0.10x | CN¥-12.37 Million | CN¥124.82 Million | ▼ -115.3% |
| 2020 | 0.65x | CN¥56.17 Million | CN¥86.97 Million | ▲ +158.3% |
| 2019 | 0.25x | CN¥56.20 Million | CN¥224.74 Million | ▲ +239.0% |
| 2018 | -0.18x | CN¥-33.50 Million | CN¥186.24 Million | ▲ +61.1% |
| 2017 | -0.46x | CN¥-67.18 Million | CN¥145.14 Million | ▼ -311.8% |
| 2016 | 0.22x | CN¥31.29 Million | CN¥143.16 Million | — |